Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market. ...